Recherche
-
A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica
(Annals of Clinical and Translational Neurology. vol. 8, n° 10, pp. 2025-2037, 2021-10)Article de revueLibre accès -
Comparison of Simoa™ and Ella™ to assess serum neurofilament-light chain in multiple sclerosis
(Annals of Clinical and Translational Neurology. vol. 8, n° 5, pp. 1141-1150, 2021-05)Article de revueLibre accès -
Determinants of therapeutic lag in multiple sclerosis
(Multiple Sclerosis Journal. vol. 27, n° 12, pp. 1838-1851, 2021-10)Article de revueLibre accès -
Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder
(Neurology. vol. 101, n° 4, pp. E438-E450, 2023-07-25)Article de revue -
Validation of a Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) and comparison with reference batteries
(2022)Document de travail - Pré-publicationLibre accès -
Structure-function coupling as a correlate and potential biomarker of cognitive impairment in multiple sclerosis
(Network Neuroscience. vol. 6, n° 2, pp. 339-356, 2022-06-01)Article de revueLibre accès -
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal
(Neurotherapeutics. vol. 19, n° 2, pp. 476-490, 2022-03)Article de revueLibre accès -
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis
(JAMA neurology. vol. 81, n° 3, pp. 273-282, 2024-03-01)Article de revueLibre accès -
Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality: The Excess Mortality vs the Cause-Specific Frameworks
(Neurology. vol. 101, n° 24, pp. E2483-E2496, 2023-12-12)Article de revue -
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment
(Neurology(R) neuroimmunology & neuroinflammation. vol. 10, n° 6, 2023-09-22)Article de revueLibre accès